Lithium and suicide prevention in bipolar disorder;Lithium et prévention du suicide dans le trouble bipolaire

Encephale

Volumn 42, Issue 3, 2016, Pages 234-241

  Benard, V ^a,b   Vaiva, G ^a,b   Masson, M ^c,d   Geoffroy, P A ^e,f,g,h  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c Clinique du Chateau de Garches   (France)

^d CENTRE HOSPITALIER SAINTE ANNE   (France)

^e INSERM   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h FONDATION FONDAMENTAL   (France)

Author keywords

Bipolar disorder; Lithium carbonate; Lithium salts; Mood stabilizer treatment; Suicidal ideation; Suicide; Suicide attempt

Indexed keywords

CARBAMAZEPINE; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN TRANSPORTER; VALPROIC ACID; LITHIUM DERIVATIVE; TRANQUILIZER;

AGGRESSION; AGGRESSIVENESS; AUTOMUTILATION; BIPOLAR DISORDER; DEPRESSION; ENDOPHENOTYPE; GENETIC VARIABILITY; HUMAN; IMPULSIVENESS; LITHIUM BLOOD LEVEL; LONG TERM CARE; MANIA; MOOD DISORDER; REVIEW; SEROTONINERGIC SYSTEM; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TREATMENT RESPONSE; PSYCHOLOGY;

ANTIMANIC AGENTS; BIPOLAR DISORDER; HUMANS; LITHIUM COMPOUNDS; SUICIDAL IDEATION; SUICIDE; SUICIDE, ATTEMPTED;

EID: 84961231306     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2016.02.006     Document Type: Article

References (72)

1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64(5):543-52.
2. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature 2011;475(7354):27-30.
3. Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions. Lancet 2013;381(9878):1663-71.
4. Geoffroy PA, Etain B, Scott J, et al. Reconsideration of bipolar disorder as a developmental disorder: importance of the time of onset. J Physiol Paris 2013;107(4):278-85.
5. Pompili M, Gonda X, Serafini G, et al. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord 2013;15(5):457-90.
6. WHO. Suicide prevention (SUPRE); 2014 http://www.who.int/mental health/prevention/suicide/suicideprevent/en/.
7. While D, Bickley H, Roscoe A, et al. Implementation of mental health service recommendations in England and Wales and suicide rates, 1997-2006: a cross-sectional and before-and-after observational study. Lancet 2012;379(9820):1005-12.
8. Gershon S, Chengappa KNR, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord 2009;11(Suppl. 2):34-44.
9. Severus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord 2014;2(1):15.
10. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013;381(9878):1672-82.
11. Yerevanian BI, Choi YM. Impact of psychotropic drugs on suicide and suicidal behaviors. Bipolar Disord 2013;15(5):594-621.
12. Niedzwiedz C, Haw C, Hawton K, et al. The definition and epidemiology of clusters of suicidal behavior: a systematic review. Suicide Life Threat Behav 2014;44(5):569-81.
13. Caine DE. Self-harm behaviour: rethinking physical and mental health. Lancet 2012;380(9853):1536-8.
14. Victor SE, Klonsky DE. Correlates of suicide attempts among self-injurers: a meta-analysis. Clin Psychol Rev 2014;34(4):282-97.
15. Foster TJ. Suicide prevention as a prerequisite for recovery from severe mental illness. Int J Psychiatry Med 2013;46(1):15-25.
16. Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006;8(5 Pt 2):625-39.
17. Müller-Oerlinghausen B, Müser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992;25(4):261-9.
18. Bocchetta A, Ardau R, Burrai C, et al. Suicidal behavior on and off lithium prophylaxis in a group of patients with prior suicide attempts. J Clin Psychopharmacol 1998;18(5):384-9.
19. Depression in adults: the treatment and management of depression in adults. Guidance and guidelines. NICE; 2009 http://www.nice.org.uk/guidance/CG90.
20. Cipriani A, Barbui C, Butler R, et al. Depression in adults: drug and physical treatments. Clin Evid 2011 [pii: 1003].
21. Oquendo MA, Galfalvy HC, Currier D, et al. Treatment of suicide attempter swith bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry 2011;168(10):1050-6.
22. Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013;346:f3646.
23. Lauterbach E, Felber W, Müller-Oerlinghausen B, et al. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand 2008;118(6):469-79.
24. Bauer M1, Bschor T, Kunz D, et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000;157(9):1429-35.
25. Müller-Oerlinghausen B. Arguments for the specificity of the antisuicidal effect of lithium. Eur Arch Psychiatry Clin Neurosci 2001;251(Suppl. 2):II72-5.
26. Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 2001;34(4):132-6.
27. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebocontrolled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65(3):432-41.
28. Bauer M, Forsthoff A, Baethge C, et al. Lithium augmentation therapy in refractory depression-update 2002. Eur Arch Psychiatry Clin Neurosci 2003;253(3):132-9.
29. Khan A, Khan SRF, Hobus J, et al. Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: role of lithium levels. J Psychiatr Res 2011;45(11):1489-96.
30. Geoffroy PA, Bellivier F, Henry C. [Treatment of manic phases of bipolar disorder: critical synthesis of international guidelines]. Encéphale 2014;40(4):330-7.
31. Cipriani A, Girlanda F, Agrimi E, et al. Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: a protocol for a randomised, independent, pragmatic, multicentre, parallel-group, superiority clinical trial. BMC Psychiatry 2013;13:212.
32. Cipriani A, Pretty H, Hawton K, et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005;162(10):1805-19.
33. Labonte B, Turecki G. The epigenetics of suicide: explaining the biological effects of early life environmental adversity. Arch Suicide Res 2010;14(4):291-310.
34. Mann JJ, Currier DM. Stress, genetics and epigenetic effects on the neurobiology of suicidal behavior and depression. Eur Psychiatry 2010;25(5):268-71.
35. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160(4):636-45.
36. Pabis DJ, Stanislav SW. Pharmacotherapy of aggressive behavior. Ann Pharmacother 1996;30(3):278-87.
37. Kovacsics CE, Gottesman II, Gould TD. Lithium's antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol 2009;49(1):175-98.
38. Ernst CL, Goldberg JF. Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 2004;12(1):14-41.
39. Courtet P, Gottesman II, Jollant F, et al. The neuroscience of suicidal behaviors: what can we expect from endophenotype strategies? Transl Psychiatry 2011;1 [pii: e7].
40. Pihlakoski L, Sourander A, Aromaa M, et al. The continuity of psychopathology from early childhood to preadolescence: a prospective cohort study of 3-12-year-old children. Eur Child Adolesc Psychiatry 2006;15(7):409-17.
41. Courtet P, Guillaume S, Sénèque M, et al. Les indications actuelles du lithium: la prévention du risque suicidaire. Ann Med Psychol Rev Psychiatr 2014;172(3):182-5.
42. Jollant F, Bellivier F, Leboyer M, et al. Impaired decision making in suicide attempters. Am J Psychiatry 2005;162(2):304-10.
43. Richard-Devantoy S, Berlim MT, Jollant F. A meta-analysis of neuropsychological markers of vulnerability to suicidal behavior in mood disorders. Psychol Med 2014;44(08):1663-73.
44. Tyano S, Zalsman G, Ofek H, et al. Plasma serotonin levels and suicidal behavior in adolescents. Eur Neuropsychopharmacol 2006;16(1):49-57.
45. Jollant F, Lawrence NL, Olié E, et al. The suicidal mind and brain: a review of neuropsychological and neuroimaging studies. World J Biol Psychiatry 2011;12(5):319-39.
46. Wingo AP, Wingo TS, Harvey PD, et al. Effects of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry 2009;70(11):1588-97.
47. Swann AC, Dougherty DM, Pazzaglia PJ, et al. Increased impulsivity associated with severity of suicide attempt history in patients with bipolar disorder. Am J Psychiatry 2005;162(9):1680-7.
48. Massot O, Rousselle JC, Fillion MP, et al. 5-HT1B receptors: a novel target for lithium. Possible involvement in mood disorders. Neuropsychopharmacol 1999;21(4):530-41.
49. Perveen T, Haider S, Mumtaz W, et al. Attenuation of stress-induced behavioral deficits by lithium administration via serotonin metabolism. Pharmacol Rep PR 2013;65(2):336-42.
50. Can A, Schulze TG, Gould TD. Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol Biochem Behav 2014;123:3-16.
51. Geoffroy PA, Bellivier F, Leboyer M, et al. Can the response to mood stabilizers be predicted in bipolar disorder? Front Biosci 2014;6:120-38.
52. Mota de Freitas D, Castro MMCA, Geraldes CFGC. Is competition between Li+ and Mg2+ the underlying theme in the proposed mechanisms for the pharmacological action of lithium salts in bipolar disorder? Acc Chem Res 2006;39(4):283-91.
53. Berridge MJ. Inositol trisphosphate and calcium signalling mechanisms. Biochim Biophys Acta 2009;1793(6):933-40.
54. Urs NM, Snyder JC, Jacobsen JPR, et al. Deletion of GSK3 in D2R-expressing neurons reveals distinct roles for arrestin signaling in antipsychotic and lithium action. Proc Natl Acad Sci U S A 2012;109(50):20732-7.
55. Chiu C-T, Wang Z, Hunsberger JG, et al. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 2013;65(1):105-42.
56. Geoffroy PA, Etain B, Sportiche S, Bellivier F. Circadian biomarkers in patients with bipolar disorder: promising putative predictors of lithium. Int J Bipolar Disord 2014;2:5, http://dx.doi.org/10.1186/2194-7511-2-5.
57. Stanley B, Jones J. Risk for suicidal behaviour in personality disorders. In: Wasserman D, Wasserman C, editors. Oxford textbook of suicidology and suicide prevention. Oxford University Press; 2009. http://www.oxfordmedicine.com/view/10.1093/med/9780198570059.001.0001/med-9780198570059-chapter-39.
58. Kovacsics CE, Gottesman II, Gould TD. Lithium's antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol 2009;49:175-98.
59. Jiménez E, Arias B, Mitjans M, et al. Association between GSK3b gene and increased impulsivity in bipolar disorder. Eur Neuropsychopharmacol 2014;24(4):510-8.
60. Lin Y-F, Huang M-C, Liu H-C. Glycogen synthase kinase 3b gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium. J Affect Disord 2013;147(1-3):401-6.
61. Malloy-Diniz LF, Neves FS, de Moraes PHP, et al. The 5-HTTLPR polymorphism, impulsivity and suicide behavior in euthymic bipolar patients. J Affect Disord 2011;133(1-2):221-6.
62. Neves FS, Silveira G, Romano-Silva MA, et al. Is the 5-HTTLPR polymorphism associated with bipolar disorder or with suicidal behavior of bipolardisorder patients? Am J Med Genet B Neuropsychiatr Genet 2008;147B(1): 114-6.
63. Stuart MJ, Baune BT. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev 2014;42:93-115.
64. Vargas HO, Nunes SOV, Pizzo de Castro M, et al. Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J Affect Disord 2013;150(3):923-30.
65. Beurel E, Jope RS. Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits. Transl Psychiatry 2014;4:e488.
66. Llorca P-M, Courtet P, Martin P, et al. Dépistage et prise en charge du trouble bipolaire: méthodologie. Encéphale 2010;36:S79-85.
67. Oruch R, Elderbi MA, Khattab HA, et al. Lithium: a review of pharmacology, clinical uses, and toxicity. Eur J Pharmacol 2014 [Internet] http://www.linkinghub.elsevier.com/retrieve/pii/S0014299914004932.
68. McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379(9817):721-8.
69. Aprahamian I, Santos FS, dos Santos B, et al. Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry 2014;75(7):e672-8.
70. Blüml V, Regier MD, Hlavin G, et al. Lithium in the public water supply and suicide mortality in Texas. J Psychiatr Res 2013;47(3):407-11.
71. Kapusta ND, Mossaheb N, Etzersdorfer E, et al. Lithium in drinking water and suicide mortality. Br J Psychiatry 2011;198(5):346-50.
72. Malhi GS, Tanious M, Das P, et al. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs 2013;27(2): 135-53.